Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 101–200 of 2,932
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 119
“5 million deaths and affect over a billion individuals [50].”
BackgroundA Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA)
Feys, S., Almyroudi, M. P., Braspenning, R., Lagrou, K., Spriet, I., Dimοpoulos, G., & Wauters, J. (2021) · Journal of Fungi · doi:10.3390/jof7121067 · Cited by 104
“Strikingly, these differences do not seem to correspond with differences in the IPA incidence J. Fungi 2021, 7, 1067 4 of 20 seen in well-known at-risk patient populations (for instance, reported to be higher for Greece than for Germany) [60].”
BackgroundInfluentialHasanin, M. S., Elbahnasawy, M. A., Shehabeldine, A. M., & Hashem, A. H. (2021) · BioMetals · doi:10.1007/s10534-021-00344-7 · Cited by 99
Hashem, A. H., Selim, T. A., Alruhaili, M. H., Selim, S., Alkhalifah, D. H. M., Jaouni, S. K. A., & Salem, S. S. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13030112 · Cited by 109
“The recent annual incidence of invasive candidiasis was 750,000 cases, respectively [6].”
BackgroundResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Salmanton‐García, J., Hoenigl, M., Gangneux, J., Segal, E., Alastruey‐Izquierdo, A., Arıkan-Akdağlı, S., Lagrou, K., Özenci, V., Vena, A., & Cornely, O. A. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00261-0 · Cited by 103
Recent Trends in the Epidemiology of Fungal Infections
Seagle, E. E., Williams, S., & Chiller, T. M. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.001 · Cited by 114
Current Landscape of Methods to Evaluate Antimicrobial Activity of Natural Extracts
González‐Pastor, R., Carrera-Pacheco, S. E., Zúñiga-Miranda, J., Rodríguez-Pólit, C., Mayorga-Ramos, A., Guamán, L. P., & Barba‐Ostria, C. (2023) · Molecules · doi:10.3390/molecules28031068 · Cited by 160
“7 million deaths annually, which is equivalent to that caused by tuberculosis and more than triple that of malaria [64,65].”
BackgroundFungal infections: Immune defense, immunotherapies and vaccines
Loh, J. T., & Lam, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114775 · Cited by 111
The global epidemiology of emerging Histoplasma species in recent years
Rodrigues, A. M., Beale, M. A., Hagen, F., Fisher, M. C., Terra, P. P. D., de Hoog, S., Brilhante, R. S. N., Cordeiro, R. D. A., Castelo‐Branco, D. D. S. C. M., Rocha, M. F. G., et al. (2020) · Studies in Mycology · doi:10.1016/j.simyco.2020.02.001 · Cited by 103
“Recent global estimates are of annual incidence of ~100 000 cases of disseminated histoplasmosis (Bongomin et al. 2017).”
BackgroundAssessing global fungal threats to humans
Xu, J. (2022) · mLife · doi:10.1002/mlf2.12036 · Cited by 116
“…treatment effects while minimizing drug resistance in both clinics and agricultural fi elds; (iii) new antifungal drugs or drug combinations; (iv) vaccines against the major fungal pathogens; and (v) better logistics in delivering effective approaches across the globe, for example 53,85,86 .”
BackgroundInfluentialPhytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance
Jadimurthy, R., Jagadish, S., Nayak, S. C., Kumar, S., Mohan, C. D., & Rangappa, K. S. (2023) · Life · doi:10.3390/life13040948 · Cited by 118
Impact of novel microbial secondary metabolites on the pharma industry
Ramírez-Rendón, D., Passari, A. K., Ruiz‐Villafán, B., Rodríguez-Sanoja, R., Sánchez, S., & Demain, A. L. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11821-5 · Cited by 108
Kolbrink, B., Scheikholeslami-Sabzewari, J., Borzikowsky, C., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100400 · Cited by 89
The role of Candida albicans stress response pathways in antifungal tolerance and resistance
Iyer, K. R., Robbins, N., & Cowen, L. E. (2022) · iScience · doi:10.1016/j.isci.2022.103953 · Cited by 88
“Global invasive candidiasis cases have been estimated at 700,000 annually, with C. albicans classified as the leading etiological agent of these nosocomial infections (Bongomin et al., 2017).”
BackgroundAg2O Nanoparticles as a Candidate for Antimicrobial Compounds of the New Generation
Gudkov, S. V., Serov, D. A., Astashev, M. E., Semenova, A., & Lisitsyn, A. B. (2022) · Pharmaceuticals · doi:10.3390/ph15080968 · Cited by 103
“5 million cases of fungal diseases have a lethal outcome [8].”
BackgroundMetal Nanoparticles to Combat Candida albicans Infections: An Update
do Carmo, P. H. F., Garcia, M. T., Figueiredo-Godoi, L. M. A., Lage, A. C. P., da Silva, N. S., & Junqueira, J. C. (2023) · Microorganisms · doi:10.3390/microorganisms11010138 · Cited by 91
“albicans is the chief pathogen due to its high prevalence in infections and phenotypic plasticity [7,11].”
Kim, H. Y., Nguyen, T. A., Kidd, S. E., Chambers, J., Alastruey‐Izquierdo, A., Shin, J.-H., Dao, A., Forastiero, A., Wahyuningsih, R., Chakrabarti, A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae042 · Cited by 123
Ahmad, A., Akbar, S., Tahir, M., Hayat, M., & Ali, F. (2022) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2022.104516 · Cited by 90
Sulfobutylether-β-cyclodextrin: A functional biopolymer for drug delivery applications
Pardeshi, C. V., Kothawade, R. V., Markad, A. R., Pardeshi, S. R., Kulkarni, A. D., Chaudhari, P. J., Longhi, M. R., Dhas, N. L., Naik, J., Surana, S. J., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.120347 · Cited by 106
Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
Bolla, P. K., Meraz, C. A., Rodriguez, V., Deaguero, I. G., Singh, M., Yellepeddi, V., & Renukuntla, J. (2019) · Molecules · doi:10.3390/molecules24173139 · Cited by 100
“Most commonly reported fungal infections are superficial in nature affecting skin, hair, nails, and mucosa however, systemic fungal infections are also reported [1,3].”
BackgroundIntharuksa, A., Kuljarusnont, S., Sasaki, Y., & Tungmunnithum, D. (2024) · Molecules · doi:10.3390/molecules29235760 · Cited by 116
Nanoparticles in Dentistry: A Comprehensive Review
Moraes, G. S., Zambom, C. R., & Siqueira, W. L. (2021) · Pharmaceuticals · doi:10.3390/ph14080752 · Cited by 114
Current research on fungi in chronic wounds
Ge, Y., & Wang, Q. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1057766 · Cited by 103
Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections
Albadr, A. A., Tekko, I. A., Vora, L. K., Ali, A., Laverty, G., Donnelly, R. F., & Singh, T. R. R. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01032-2 · Cited by 93
“Treatment of fungal infection is challenging because of anterior ocular barriers like corneal epithelium and tear fluid, limiting drug availability and the lack of efficient drug delivery systems [4].”
BackgroundQadri, H., Shah, A. H., Ahmad, S. M., Alshehri, B., Almilaibary, A., & Mir, M. A. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103376 · Cited by 107
“The majority of these fungi infect immune-compromised people who have HIV, asthma, diabetes, undergoing cancer treatments, autoimmune disorder therapies, and other innovative treatments (K. Redhu et al., 2016, Bongomin et al., 2017).”
Antibacterial and Antifungal Sesquiterpenoids: Chemistry, Resource, and Activity
Li, H.-Y., Yang, W., Zhou, X., Shao, F., Shen, T., Guan, H.-Y., Zheng, J., & Zhang, L. (2022) · Biomolecules · doi:10.3390/biom12091271 · Cited by 84
“Therefore, it is a challenge that antibiotic resistance is not easy to overcome, requiring the development of newer antibacterial and antifungal drugs [3].”
BackgroundPfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Steenwyk, J. L., Mead, M. E., Knowles, S. L., Raja, H. A., Roberts, C. D., Bader, O., Houbraken, J. A. M. P., Goldman, G. H., Oberlies, N. H., & Rokas, A. (2020) · Genetics · doi:10.1534/genetics.120.303549 · Cited by 81
El-Baz, A. M., Mosbah, R., Goda, R. M., Mansour, B., Sultana, T., Dahms, T. E. S., & El-Ganiny, A. M. (2021) · Antibiotics · doi:10.3390/antibiotics10010081 · Cited by 93
“The incidence of fungal infections, including candidiasis, has increased worldwide over the past few decades [1].”
BackgroundEpigenetic mechanisms of drug resistance in fungi
Chang, Z., Yadav, V., Lee, S. C., & Heitman, J. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103253 · Cited by 92
Ivanov, M., Kannan, A., Stojković, D. S., Glamočlija, J., Calhelha, R. C., Ferreira, I. C. F. R., Sanglard, D., & Sokóvić, M. (2020) · Pharmaceuticals · doi:10.3390/ph14010027 · Cited by 79
“albicans is worldwide listed as one of the most common causes of human fungal infections with around 700,000 cases of invasive and 2,000,000 cases of oral candidiasis recorded annually [8].”
BackgroundResponses of Mast Cells to Pathogens: Beneficial and Detrimental Roles
Jiménez, M., Cervantes‐García, D., Córdova-Dávalos, L. E., Pérez‐Rodríguez, M. J., González‐Espinosa, C., & Salinas, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685865 · Cited by 88
Halat, D. H., Younes, S., Mourad, N., & Rahal, M. K. (2022) · Membranes · doi:10.3390/membranes12121171 · Cited by 93
“They can range in severity from superficial infections that affect the skin or nails, to severe invasive or disseminated infections that are life-threatening [3,4].”
BackgroundEnvironmental reservoirs of the drug-resistant pathogenic yeast Candida auris
Akinbobola, A., Kean, R., Hanifi, S. M. A., & Quilliam, R. S. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011268 · Cited by 88
“candidiasis is approximately 750,000 and is associated with a high mortality rate, particularly in critically ill patients and those with compromised immunity [11,13].”
BackgroundJenks, J. D., Prattes, J., Frank, J., Spiess, B., Mehta, S. R., Boch, T., Buchheidt, D., & Hoenigl, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1281 · Cited by 77
“Aspergillus species cause over 300°000 cases of invasive aspergillosis (IA) annually, with a mortality rate ranging from 30 to 80% [1, 2].”
BackgroundCandida albicans and candidalysin in inflammatory disorders and cancer
Ho, J., Camilli, G., Griffiths, J. S., Richardson, J. P., Kichik, N., & Naglik, J. R. (2021) · Immunology · doi:10.1111/imm.13255 · Cited by 77
Salmanton‐García, J., Au, W., Hoenigl, M., Chai, L. Y. A., Badali, H., Basher, A., Brockhoff, R. A., Chen, S. C. ‐., Chindamporn, A., Chowdhary, A., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106718 · Cited by 81
“However, this may not apply worldwide, particularly in regions where endemic fungi are present, such as Asia/Pacific [1–4] .”
BackgroundEmami, S., Ghobadi, E., Saednia, S., & Hashemi, S. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.020 · Cited by 87
Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections
Kischkel, B., Rossi, S. A., Santos, S. R. D., Nosanchuk, J. D., Travassos, L. R., & Taborda, C. P. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00463 · Cited by 81
Rodrigues, M. L., & Albuquerque, P. C. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006479 · Cited by 86
Rossatto, F. C. P., Tharmalingam, N., Escobar, I. E., d’Azevedo, P. A., Zimmer, K. R., & Mylonakis, E. E. (2021) · Journal of Fungi · doi:10.3390/jof7090763 · Cited by 89
Pathadka, S., Yan, V. K. C., Neoh, C. F., Al‐Badriyeh, D., Kong, D. C. M., Slavin, M. A., Cowling, B. J., Hung, I. F., Wong, I. C. K., & Chan, E. W. (2022) · Drugs · doi:10.1007/s40265-022-01751-x · Cited by 91
“Superficial nail and skin infections are the most common type of fungal infections [13] with a prevalence higher than other skin diseases affecting more than one-fourth of the world’s population, and is currently listed as one of 15 prevalent global medical problems [15, 16].”
BackgroundDias, J. D. N., de-Souza-Silva, C. M., de Araújo, A. R., Souza, J. M. T., Júnior, P. H. D. H. V., Cabral, W. F., da Silva, M. D. G., Eaton, P. J., Leite, J. R. S. A., Nicola, A. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67041-2 · Cited by 86
Skin Immunity to Dermatophytes: From Experimental Infection Models to Human Disease
Burstein, V. L., Beccacece, I., Guasconi, L., Mena, C. J., Cervi, L., & Chiapello, L. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605644 · Cited by 87
“In addition to causing symptomatic infections with different severity degrees (Figure 1), dermatophytes also colonize 30%– 70% of the human population without causing clinical disease (1, 2, 133), thus these keratin parasites could be considered as a component of the human microbiota.”
BackgroundEkeng, B. E., Davies, A. A., Osaigbovo, I. I., Warris, A., Oladele, R. O., & Denning, D. W. (2022) · Journal of Fungi · doi:10.3390/jof8050460 · Cited by 89
“clinicians remains poor compared to TB [1].”
Self-citationBurden of Serious Fungal Infections in India
Ray, A., Adarsh Aayilliath, K., Banerjee, S., Chakrabarti, A., & Denning, D. W. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac603 · Cited by 103
“1093/ofid/ofac603 Globally, fungal diseases are known to impact millions of lives [1].”
BackgroundSelf-citationInvasive Pulmonary Aspergillosis
Ledoux, M., & Herbrecht, R. (2023) · Journal of Fungi · doi:10.3390/jof9020131 · Cited by 90
“On the whole, annual incidence of IA is estimated > 300,000, among ≈10 million patients at risk, in comparison with ≈3,000,000 patients sharing the global burden of CPA, ≈4,800,000 ABPA in asthma and >6000 ABPA in cystic fibrosis [15].”
Swidergall, M., Solis, N. V., Wang, Z., Phan, Q. T., Marshall, M. E., Lionakis, M. S., Pearlman, E., & Filler, S. G. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.020 · Cited by 73
Updates in Laboratory Diagnostics for Invasive Fungal Infections
Salcedo, D. A. T., & Powers‐Fletcher, M. V. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01487-19 · Cited by 102
Janbon, G., Quintin, J., Lanternier, F., & d’Enfert, C. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0071-2 · Cited by 102
“9 million persons every year in the word [13].”
Luliconazole vesicular based gel formulations for its enhanced topical delivery
Kaur, M., Singh, K., & Jain, S. K. (2019) · Journal of Liposome Research · doi:10.1080/08982104.2019.1682602 · Cited by 76
McKloud, E., Delaney, C., Sherry, L., Kean, R., Williams, S., Metcalfe, R., Thomas, R., Rautemaa‐Richardson, R., Gerasimidis, K., Nile, C. J., et al. (2021) · mSystems · doi:10.1128/msystems.00622-21 · Cited by 100
Clinical Manifestations of Human Exposure to Fungi
Oliveira, M. T. D. S., de Oliveira, D. M., Lisboa, C., Boechat, J. L., & Delgado, L. (2023) · Journal of Fungi · doi:10.3390/jof9030381 · Cited by 96
“The most common infections are oral candidiasis, vulvovaginitis, and balanitis (Figure 2E,F) [14].”
BackgroundHoenigl, M., Gangneux, J., Segal, E., Alanio, A., Chakrabarti, A., Chen, S. C. ‐., Govender, N., Hagen, F., Klimko, N., Meis, J. F., et al. (2018) · Mycoses · doi:10.1111/myc.12836 · Cited by 72
Chronic pulmonary aspergillosis update: A year in review
Barac, A. M., Kosmidis, C., Alastruey‐Izquierdo, A., Salzer, H. J. F., & CPAnet (2019) · Medical Mycology · doi:10.1093/mmy/myy070 · Cited by 79
Fungal Extracellular Vesicles as Potential Targets for Immune Interventions
Freitas, M. S., Bonato, V. L. D., Pessoni, A. M., Rodrigues, M. L., Casadevall, A., & Almeida, F. B. D. R. (2019) · mSphere · doi:10.1128/msphere.00747-19 · Cited by 73
“Deep mycoses, such as cryptococcosis, candidiasis, and aspergillosis, are responsible for approximately 1,270,000 annual global cases, and the mortality rates from these mycoses are comparable to those from malaria (24, 25).”
BackgroundMechanisms of triazole resistance in Aspergillus fumigatus
Nywening, A. V., Rybak, J. M., Rogers, P. D., & Fortwendel, J. R. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15274 · Cited by 87
“…recently estimated the current burden of aspergilloses worldwide, approximating 4.8 million cases of ABPA, 3 million cases of chronic pulmonary aspergillosis (CPA) and between 250, 000 and 400, 000 cases of IA annually (Brown et al., 2012; Bongomin et al., 2017; CDC, 2019; Bongomin et al., 2020).”
BackgroundInfluentialGnat, S., Łagowski, D., Nowakiewicz, A., & Dyląg, M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15084 · Cited by 86
“The greater prevalence, as up to 1 billion people have skin mycoses, makes these infections only slightly less common than headaches or dental caries (Bongomin et al. 2017).”
BackgroundEvolution of antifungal resistance in the environment
van Rhijn, N., & Rhodes, J. L. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02055-y · Cited by 94
“The incidence of fungal infections is rising globally, which is thought to be fuelled by increasing at-risk populations and socio-economic, geo-ecological and climate change characteristics 3,4 .”
A CRISPR Interference Platform for Efficient Genetic Repression in Candida albicans
Wensing, L. F., Sharma, J., Uthayakumar, D., Proteau, Y., Chavez, A., & Shapiro, R. S. (2019) · mSphere · doi:10.1128/msphere.00002-19 · Cited by 75
“transcriptional repressor Sin3 (52, 62); and (2) Mig1, a well-characterized S.”
Candida biofilm production is associated with higher mortality in patients with candidaemia
Vitális, E., Nagy, F., Tóth, Z., Forgács, L., Bozó, A., Kardos, G., Majoros, L., & Kovács, R. (2020) · Mycoses · doi:10.1111/myc.13049 · Cited by 74
“Mean age (range) 61 (1-90) 63 (1-89) 61 (1-90) .”
In-silico design of a multivalent epitope-based vaccine against Candida auris
Akhtar, N., Joshi, A., Kaushik, V., Kumar, M., & Mannan, M. A.-U. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104879 · Cited by 74
Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis
Maitre, T., Cottenet, J., Godet, C., Roussot, A., Carime, N. A., Ok, V., Parrot, A., Bonniaud, P., Quantin, C., & Cadranel, J. L. (2021) · European Respiratory Journal · doi:10.1183/13993003.03345-2020 · Cited by 76
“The prevalent rate of CPA in France was consistent with the limited data available for other low TB incidence countries [17].”
BackgroundResultA Review on Antifungal Efficiency of Plant Extracts Entrenched Polysaccharide-Based Nanohydrogels
Kaur, N., Bains, A., Kaushik, R., Dhull, S. B., Fogarasi, M., & Chawla, P. (2021) · Nutrients · doi:10.3390/nu13062055 · Cited by 90
“In the skin, fungi lead to subcutaneous infections, and over the past years, the cases of fungal skin infections have been increasing rapidly, especially in immune-compromised individuals [4].”
BackgroundMajocchi’s granuloma: current perspectives
Boral, H., Durdu, M., & İlkit, M. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s145027 · Cited by 72
Vitamin Biosynthesis as an Antifungal Target
Meir, Z., & Osherov, N. (2018) · Journal of Fungi · doi:10.3390/jof4020072 · Cited by 75
“Recent estimates have identified a global burden of almost two million patients with systemic and invasive fungal infections, including ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~220,000 cases of cryptococcal meningitis, and ~1…”
BackgroundCurcumin and Its Derivatives: A Review of Their Biological Activities
Oglah, M. K., Mustafa, Y. F., Bashir, M. K., & Jasim, M. H. M. (2020) · Systematic Reviews in Pharmacy · doi:10.5530/srp.2020.3.60 · Cited by 109
“particularly those caused by Candida species, has elevated dramatically worldwide (19).”
BackgroundMucormycosis: time to address this deadly fungal infection
Stone, N. R. H., Gupta, N. R., & Schwartz, I. S. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00148-8 · Cited by 68
Ten decadal advances in fungal biology leading towards human well-being
Mapook, A., Hyde, K. D., Hassan, K., Kemkuignou, B. M., Čmoková, A., Surup, F., Kuhnert, E., Paomephan, P., Cheng, T., de Hoog, S., et al. (2022) · Fungal Diversity · doi:10.1007/s13225-022-00510-3 · Cited by 81
AFP-MFL: accurate identification of antifungal peptides using multi-view feature learning
Fang, Y., Xu, F., Wei, L., Jiang, Y., Chen, J., Wei, L., & Wei, D. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac606 · Cited by 72
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
HIV-Associated Histoplasmosis: Current Perspectives
Myint, T., Leedy, N., Cari, E. V., & Wheat, L. J. (2020) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s185631 · Cited by 86
Goddard, F. G. B., Ban, R., Barr, D. B., Brown, J. M., Cannon, J. L., Colford, J. M., Eisenberg, J. N. S., Ercümen, A., Petach, H., Freeman, M. C., et al. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.0c02421 · Cited by 77
Zhou, L., Zhao, X., Li, M., Lu, Y. P., Ai, C., Jiang, C., Liu, Y., Pan, Z., & Shi, J. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11296-w · Cited by 69
“More than 150 million of patients suffer from serious fungal infections worldwide (Bongomin et al. 2017).”
BackgroundSharma, R., Shrivastava, S., Singh, S. K., Kumar, A., Saxena, S., & Singh, R. K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab422 · Cited by 74
Secreted Aspartic Proteinases: Key Factors in Candida Infections and Host-Pathogen Interactions
Braś, G., Satała, D., Juszczak, M., Kulig, K., Wronowska, E., Bednarek, A., Zawrotniak, M., Rąpała‐Kozik, M., & Karkowska‐Kuleta, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094775 · Cited by 86
Bongomin, F., Asio, L. G., Baluku, J. B., Kwizera, R., & Denning, D. W. (2020) · Journal of Fungi · doi:10.3390/jof6020075 · Cited by 80
“Globally, it is estimated that over 3 million people suffer from CPA [12].”
BackgroundSelf-citationDudhipala, N. R., & Youssef, A. A. A. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.104953 · Cited by 71
Systemic Mycoses: A Potential Alert for Complications in COVID-19 Patients
Segrelles‐Calvo, G., Araújo, G. R. D. S., & Frasés, S. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0156 · Cited by 71
Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 65
“[4] reported mortality rates in the UK in excess of 40%.”
BackgroundRiera, F. O., Caeiro, J. P., Angiolini, S. C., Vigezzi, C., Rodriguez, E., Icely, P. A., & Sotomayor, C. E. (2022) · Antibiotics · doi:10.3390/antibiotics11070877 · Cited by 65
A One Health approach to overcoming fungal disease and antifungal resistance
Woods, M., McAlister, J. A., & Geddes‐McAlister, J. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1610 · Cited by 81
Extracellular Vesicles in Fungi: Composition and Functions
Martins, S. D. T., Szwarc, P., Goldenberg, S., & Alves, L. R. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_141 · Cited by 74
The CRISPR toolbox in medical mycology: State of the art and perspectives
Morio, F., Lombardi, L., & Butler, G. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008201 · Cited by 68
Hagan, A. K., Topçuoğlu, B. D., Gregory, M. E., Barton, H. A., & Schloss, P. D. (2020) · mBio · doi:10.1128/mbio.01680-20 · Cited by 63
dos Reis, T. F., de Castro, P. A., Bastos, R. W., Pinzan, C. F., Souza, P. F. N., Ackloo, S. Z., Hossain, M. A., Drewry, D. H., Alkhazraji, S., Ibrahim, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37573-y · Cited by 69
“Images were deindentified and assigned an overall disease score (range 0–4) by two blinded reviewers based on server criteria, including (1) area of opacification, (2) density of opacification, and (3) surface irregulating.”
MethodMadkhali, O. A. A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101733 · Cited by 76
“Human FIs are markedly different from other infections.”
InfluentialFernández-García, R., & Fraguas‐Sánchez, A. I. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121584 · Cited by 78
“…the incidence of these infections has risen, likely due to the growing population of immune-compromised individuals, resulting from factors such as organ transplants, cancer treatments, autoimmune diseases, acquired immunodeficiency syndrome (AIDS), and corticosteroid therapies, among others [133].”
Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63
Borghi, M., Pariano, M., Solito, V., Puccetti, M., Bellet, M. M., Stincardini, C., Renga, G., Vacca, C., Sellitto, F., Mosci, P., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02364 · Cited by 63
“Clinical manifestations of candidiasis range from cutaneous and mucosal infections to invasive candidiasis with bloodstream and deep-seated infections (1), with distinct prevalence (2), and pathogenesis (3).”
BackgroundMortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999–2018
Rayens, E., Norris, K. A., & Cordero, J. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab336 · Cited by 63
“The true healthcare cost is likely much higher due to extensive underdiagnosis and a lack of public health surveillance [26], resulting in a continued inability to fully assess the burden of fungal disease in the United States.”
BackgroundSocial determinants of health as drivers of fungal disease
Jenks, J. D., Prattes, J., Wurster, S., Sprute, R., Seidel, D., Oliverio, M., Egger, M., del Río, C., Sati, H. F., Cornely, O. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102325 · Cited by 76
Yang, F., Scopel, E. F. C., Li, H., Sun, L.-L., Kawar, N., Cao, Y.-B., Jiang, Y.-Y., & Berman, J. (2023) · mBio · doi:10.1128/mbio.00227-23 · Cited by 62
Burden of fungal asthma in Africa: A systematic review and meta-analysis
Kwizera, R., Musaazi, J., Meya, D. B., Worodria, W. O., Bwanga, F., Kajumbula, H., Fowler, S. J., Kirenga, B., Gore, R. B., & Denning, D. W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216568 · Cited by 68
“In a recent review article published in 2017 which discussed the accuracy of estimates of the burden of fungal infections in 43 countries, the global prevalence of fungal asthma was estimated at over ten million cases annually [73].”
BackgroundSelf-citationde Jong, A. W., Dieleman, C., Carbia, M., Tap, R. M., & Hagen, F. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.03220-20 · Cited by 67
“Tested yeast species were as follows: (1) Pichia kudriavzevii CBS2050 (syn.”
InfluentialBrandão, J. C., Gangneux, J., Arıkan-Akdağlı, S., Barac, A. M., Bostănaru, A.-C., Brito, S., Bull, C. M., Çerikçioğlu, N., Chapman, B., Efstratiou, M. A., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.146598 · Cited by 73
“Allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitization (SAFS), Aspergillus bronchitis and allergic Aspergillus rhinosinusitis account for a considerable fungal disease burden (Bongomin et al., 2017).”
BackgroundPfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 70
Emergence and evolution of virulence in human pathogenic fungi
Siscar-Lewin, S., Hube, B., & Brunke, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.12.013 · Cited by 75
Francesco, M. A. D. (2023) · Pathogens · doi:10.3390/pathogens12111305 · Cited by 81
“The incidence of IA, which is estimated to a ff ect 250,000 people globally, is still growing [38].”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.